Company: EUDAW
Filing Date: 2025-08-08
Form Type: 424B5
Source: 0001493152-25-011729
Chunk: 0

Company: EUDA Health Holdings Ltd
Filing Date: 2025-08-08
Form: 424B5
Chunk 0
---
Filed Pursuant to Rule 424(b)(5)

Registration No. 333-282723

PROSPECTUS SUPPLEMENT

(To Prospectus dated November 4, 2024)

<div align='center'>EUDA HEALTH HOLDINGS LIMITED

US$10,000,000 Convertible Note

Up to 5,000,000 Ordinary Shares issuable upon conversion of the $10,000,000 Convertible Note</div>

We are offering, in a registered direct offering to Indigo Capital LP, an accredited investor (the “Investor”), one or more convertible promissory notes in amounts not to exceed US$10,000,000 principal amount, in the aggregate, of convertible notes (the “Convertible Notes”). Each Convertible Note, if issued pursuant to a put request in an amount requested by the Company and accepted by the Investor (each, an “Advance”), shall be convertible into newly-issued ordinary shares, no par value each, of the Company (“Ordinary Shares”) at a conversion rate equal to 85% of the price of the Company’s Ordinary Shares on Nasdaq on the date the Investor submits a conversion notice to the Company (the “Conversion Notice”). The Advance relating to each Note shall be the purchase price of each Convertible Note and shall be equal to ninety percent (90.00%) of the principal amount of the Convertible Note.

This prospectus supplement covers up to 5,000,000 Ordinary Shares, issuable from time to time upon conversion of the Convertible Note and in lieu of the payment of interest payable on the Convertible Note. The Ordinary Shares issuable upon conversion of the Convertible Notes, are being issued pursuant to this prospectus supplement, the accompanying base prospectus, that certain convertible promissory note purchase agreement, dated August 1, 2025, by and between the Company and the Investor.

No placement agent is involved in this offering.

Our ordinary shares are listed on the NASDAQ Capital Market under the symbol “EUDA”. On August 7, 2025, the closing price of our ordinary shares on the Nasdaq Capital Market was US$2.83.

There is no established trading market for the Convertible Notes, and we do not expect a market to develop. In addition, we do not intend to apply for the listing of the Convertible Notes on any national securities exchange or other trading market.

As of the date of this prospectus supplement, the aggregate market value of the voting and non-voting common equity held